Detection rate and clinical pattern of prostate cancer in Kuwait: a single-center experience

Affiliations

01 January 2011

-

doi: 10.1159/000319762


Abstract

Objective: To determine the detection rate and clinical pattern of prostate cancer in Kuwait.

Subjects and methods: One hundred and fifty-three males suspected of having prostate cancer based on elevation of prostate-specific antigen (PSA) of more than 4 ng/ml underwent transrectal-ultrasound (TRUS)-guided needle biopsy of the prostate between January 2003 and January 2008; these formed the study group. Analysis of prostate cancer was based on age, prostate volume, PSA level and on finding any abnormality based on a combination of the diagnostic tools.

Results: A diagnosis of prostate cancer was histologically confirmed in 42 (27.4%) patients. In those aged <55, 56-65, 66-75 and >76 years, the detection rates were 16.7, 17.6, 33.3 and 40.7%, respectively. In those with prostate volumes of >71, 51-70, 31-50 and <30 g, the detection rates were 18.2, 23.8, 30.8 and 42.9%, respectively. When the PSA levels were divided into groups of 4-10, 10-20, 20-100 and >100 ng/ml, the cancer detection rate was 11.8, 20.5, 47.1 and 83.3%, respectively. When 1, 2 and 3 of the 3 diagnostic tools (digital rectal examination, PSA, TRUS) were abnormal, the detection rate was 15.6, 27.9 and 80%, respectively.

Conclusions: Our data showed that the prostate cancer rate differs according to the region and that the rate was low in our center. Higher PSA and higher number of diagnostic tools with abnormal findings were associated with a higher incidence of prostate cancer.


Similar articles

Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.

Men S, Cakar B, Conkbayir I, Hekimoglu B.J Exp Clin Cancer Res. 2001 Dec;20(4):473-80.PMID: 11876539

Results of prostate biopsies in a teaching hospital in Western Saudi Arabia.

Tayib AM, Mosli HA, Al-Ammari AA.Saudi Med J. 2003 Aug;24(8):859-62.PMID: 12939672

Detection of prostate cancer at low and intermediate serum prostate-specific antigen levels in a country with a low incidence of prostate cancer.

Lee SE, Byun SS, Park HK, Shim HB, Ku JH.Jpn J Clin Oncol. 2006 Jun;36(6):376-80. doi: 10.1093/jjco/hyl032. Epub 2006 May 30.PMID: 16735369

Prostate cancer screening at an equal access tertiary care center: its impact 10 years after the introduction of PSA.

Soderdahl DW, Hernandez J.Prostate Cancer Prostatic Dis. 2002;5(1):32-5. doi: 10.1038/sj.pcan.4500555.PMID: 15195128 Review.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies.

Coley CM, Barry MJ, Fleming C, Wasson JH, Fahs MC, Oesterling JE.Urology. 1995 Aug;46(2):125-41. doi: 10.1016/s0090-4295(99)80181-2.PMID: 7542817 Review. No abstract available.


Cited by

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.

Wang ZB, Wei CG, Zhang YY, Pan P, Dai GC, Tu J, Shen JK.Biomed Res Int. 2021 Oct 11;2021:3995789. doi: 10.1155/2021/3995789. eCollection 2021.PMID: 34671673 Free PMC article.

Detection rate of prostate cancer following 12-core extended biopsy in a Semi-urban Nigerian Tertiary Hospital.

Ogbetere FE, Irekpita E.Urol Ann. 2021 Apr-Jun;13(2):150-155. doi: 10.4103/UA.UA_136_20. Epub 2021 Apr 13.PMID: 34194141 Free PMC article.

TRUS Biopsy Yield in Indian Population: A Retrospective Analysis.

Patil SR, Pawar PW, Sawant AS, Patil AV, Narwade SS, Mundhe ST, Savalia AJ, Tamhankar AS.J Clin Diagn Res. 2017 Feb;11(2):PC01-PC05. doi: 10.7860/JCDR/2017/25473.9251. Epub 2017 Feb 1.PMID: 28384926 Free PMC article.


KMEL References